trending Market Intelligence /marketintelligence/en/news-insights/trending/_-O_slMVFN-ULrgxWnTBTw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Aurinia closes US$191.7M common stock offering to fund drug launch activities

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Aurinia closes US$191.7M common stock offering to fund drug launch activities

Aurinia Pharmaceuticals Inc. has raised about US$191.7 million in gross proceeds via a common stock offering.

The Canadian biotechnology company sold a total of 12,782,439 common shares at US$15 apiece. This includes 1,667,274 shares sold to the underwriters in a fully exercised overallotment option provided by the company.

Victoria, British Columbia-based Aurinia will use the net proceeds from the offering to prepare for pre-commercialization and launch activities. The company recently reported positive results for its kidney inflammation medicine voclosporin. The company plans to file for approval with the U.S. Food and Drug Administration for the drug in the first half of 2020.

Jefferies LLC and SVB Leerink LLC served as joint book-running managers for the offering, and H.C. Wainwright & Co. LLC, Oppenheimer & Co. Inc. and Bloom Burton Securities Inc. were co-managers.